Open Access

[Corrigendum] Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells

  • Authors:
    • Wei Du
    • Changhe Pang
    • Yake Xue
    • Qingjun Zhang
    • Xinting Wei
  • View Affiliations

  • Published online on: March 15, 2021     https://doi.org/10.3892/ol.2021.12636
  • Article Number: 375
  • Copyright : © Du et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Article

Oncol Lett 10: [Related article:] 3266-3270, 2015; DOI: 10.3892/ol.2015.3699

Following the publication of the above article, an interested reader drew to the authors’ attention that lane 1 of the pMEK/BT325 cells panel in Fig. 3A appeared strikingly similar to lane 1 of the BCL-2 / C6 cells panel in Fig. 5B, albeit the protein band was inverted. Furthermore, lanes 1–3 of the MEK / C6 cells panel in Fig. 3B looked strikingly similar to lanes 1–3 of the GAPDH / BT325 cells panel in Fig. 5A.

The authors re-examined their original data, and realized that some of the data featured in Fig. 3 had been assembled incorrectly owing to the large number of proteins that had been investigated, and given the fact that not only one person was responsible for generating these data. The corrected version of Fig. 3 is shown opposite. Note that the corrections made to this figure do not affect the overall conclusions reported in the paper. The authors are grateful to the Editor of Oncology Letters for allowing them the opportunity to publish this corrigendum, and apologize to the readership for any inconvenience caused.

Related Articles

Journal Cover

May-2021
Volume 21 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Du W, Pang C, Xue Y, Zhang Q and Wei X: [Corrigendum] Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells. Oncol Lett 21: 375, 2021.
APA
Du, W., Pang, C., Xue, Y., Zhang, Q., & Wei, X. (2021). [Corrigendum] Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells. Oncology Letters, 21, 375. https://doi.org/10.3892/ol.2021.12636
MLA
Du, W., Pang, C., Xue, Y., Zhang, Q., Wei, X."[Corrigendum] Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells". Oncology Letters 21.5 (2021): 375.
Chicago
Du, W., Pang, C., Xue, Y., Zhang, Q., Wei, X."[Corrigendum] Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells". Oncology Letters 21, no. 5 (2021): 375. https://doi.org/10.3892/ol.2021.12636